Regeneron Pharmaceuticals, Inc. (REGN) Receives Consensus Recommendation of “Hold” from Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been assigned an average recommendation of “Hold” from the thirty research firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $469.95.

A number of equities analysts recently commented on REGN shares. Zacks Investment Research cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Jefferies Group reaffirmed a “hold” rating and issued a $500.00 target price (up from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, September 29th. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 31st. Finally, Evercore ISI decreased their target price on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating on the stock in a report on Thursday, November 16th.

Regeneron Pharmaceuticals (REGN) traded up $3.23 during midday trading on Thursday, hitting $361.86. The stock had a trading volume of 1,292,671 shares, compared to its average volume of 908,013. Regeneron Pharmaceuticals has a 12-month low of $340.09 and a 12-month high of $543.55. The company has a market cap of $38,540.00, a PE ratio of 31.69, a price-to-earnings-growth ratio of 1.44 and a beta of 1.56. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. During the same period last year, the firm earned $3.13 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.0% compared to the same quarter last year. analysts expect that Regeneron Pharmaceuticals will post 13.55 EPS for the current fiscal year.

In other news, CFO Robert E. Landry sold 189 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares in the company, valued at $5,060,204.94. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Robert E. Landry sold 663 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $498.60, for a total value of $330,571.80. Following the transaction, the senior vice president now owns 10,099 shares of the company’s stock, valued at approximately $5,035,361.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,352 shares of company stock worth $2,037,772. Insiders own 10.80% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Oppenheimer & Co. Inc. grew its position in shares of Regeneron Pharmaceuticals by 20.6% during the second quarter. Oppenheimer & Co. Inc. now owns 7,007 shares of the biopharmaceutical company’s stock valued at $3,441,000 after purchasing an additional 1,199 shares in the last quarter. Dupont Capital Management Corp purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $220,000. Shell Asset Management Co. grew its position in shares of Regeneron Pharmaceuticals by 24.1% during the third quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock valued at $5,565,000 after purchasing an additional 2,999 shares in the last quarter. Blair William & Co. IL grew its position in shares of Regeneron Pharmaceuticals by 4.8% during the second quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock valued at $841,000 after purchasing an additional 79 shares in the last quarter. Finally, Principal Financial Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 2.4% during the second quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock valued at $56,580,000 after purchasing an additional 2,646 shares in the last quarter. Hedge funds and other institutional investors own 69.47% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Receives Consensus Recommendation of “Hold” from Brokerages” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/30/regeneron-pharmaceuticals-inc-regn-receives-consensus-recommendation-of-hold-from-brokerages.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply